CBL0137

CBL0137 is an inhibitor of NF-kB and p53 used in studies of NF-kB Signaling and Immune Signaling and related signaling programs. In practice, this places the compound in experiments that measure inflammatory transcriptional control and stress-responsive survival signaling and cytokine-mediated signaling and inflammatory effector responses in cancer, cell cycle, and epigenetics models.

By inhibiting NF-kB and p53, CBL0137 can be used to examine inflammatory transcriptional control and stress-responsive survival signaling and cytokine-mediated signaling and inflammatory effector responses. The signaling pathway modulator annotation adds relevance to pathway-reporter and mechanistic-phenotyping studies, together with downstream-response mapping in the same experimental setting. In cancer, cell cycle, and epigenetics models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving NF-kB and p53
• Pathway perturbation studies connected to NF-kB Signaling and Immune Signaling and related signaling programs
• Concentration-response inhibition and target-dependence studies
• Pathway-reporter and mechanistic-phenotyping studies

Overall, CBL0137 is appropriate when a defined chemical perturbant is needed to connect NF-kB and p53 with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in cancer, cell cycle, and epigenetics models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.